Vasiliki Gkalea

Dr. Vasiliki Gkalea

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
VGVasiliki Gkalea
Vasiliki Gkalea
DFDespina Fotiou
Despina Fotiou
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
EKEfstathios Kastritis
Efstathios Kastritis
The current review provides an overview of the thrombotic risk observed in patients with MG who do not otherwise require treatment. We discuss clinical and biomarker studies that highlight the heterogenous hemostatic profile observed in these patients and how knowledge has evolved over the past 20 years. Biomarker studies suggest shared biologic features between multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), which involves both hypercoagulability and platelet activation. Hemostatic abnormalities identified in MGUS patients cannot be translated into clinical practice as they lack correlation to clinical events. The prothrombotic phenotype of MGUS patients has not been ascertained yet, but novel data on coagulation markers are promising. We also review rare conditions associated with the thrombogenic properties of the monoclonal protein that predispose to arterial, venous or microthrombotic events and demonstrate that the M-protein can be linked to clinically significant thrombotic events. Cryoglobulinemia, cryofibrinogenemia, cryo-crystaloglobulinemia and MG-related antiphospholipid syndrome are reviewed. We propose the new umbrella term “monoclonal gammopathy of thrombotic significance” (MGTS) to refer to significant, recurrent thrombotic events in patients with MGUS that provide a rationale for targeting the underlying plasma cell clone. Identifying MGUS patients at high risk for thrombotic events is currently a challenge.

1 December 2019 in The American Journal of Medicine
Verified
Journal Article
Closed access
CBClaude Bachmeyer
Claude Bachmeyer
RBRim Bourguiba
Rim Bourguiba
VGVasiliki Gkalea
Vasiliki Gkalea
LPLoula Papageorgiou
Loula Papageorgiou

24 October 2025 in Proteomics
Verified
Journal Article
Open access
Paraskevi KarousiParaskevi Karousi
Paraskevi Karousi
MVMaria Voumvouraki
Maria Voumvouraki
PNPanagiota Efstathia Nikolaou
Panagiota Efstathia Nikolaou
Ioannis KolliasIoannis Kollias
Ioannis Kollias
FPFoteini Paradeisi
Foteini Paradeisi
JCJulie Courraud
Julie Courraud
Bottom‐up proteomics relies on efficient and repeatable sample preparation for accurate protein identification and precise quantification. This study evaluates the performance of adapted SPEED (Sample Preparation by Easy Extraction and Digestion) protocol, a simplified, detergent‐free approach tailored for various biological matrices, including lysis‐resistant samples. Protein extraction and denaturation steps were refined for 8 biological matrices enabling standardized, cheap, and scalable proteomics analysis on 96‐well plates. For tissue samples requiring downstream applications like Western blotting, we used a low‐detergent RIPA buffer. Notably, the protocols demonstrate remarkable down‐scalability, enabling robust proteomics measurements from as few as 3000 cells per sample for preparation and even down to 300 cells per LC‐MS/MS analysis. Key advancements include a 30‐min nanoLC‐MS/MS run, achieving a 15–20 samples‐per‐day throughput, and leveraging the power of diaPASEF using thoroughly optimized DIA‐windows to enhance proteome coverage. These adaptations streamline workflows, enabling proteomics analyses in matrices with challenging physical and biochemical properties. This study underscores the importance of early‐stage optimization and feasibility testing in proteomics pipelines to inform study design and sample selection. By showcasing robust, scalable adaptations of the SPEED protocol, we provide a foundation for reproducible, high‐throughput proteomic studies across diverse biological contexts.

12 April 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
VGVasiliki Gkalea
Vasiliki Gkalea
STSolange Tang
Solange Tang
RFRemi Favier
Remi Favier
CKCharlène Kuadjovi
Charlène Kuadjovi
EBEdouard Bégon
Edouard Bégon
LBLaurent Blum
Laurent Blum

22 December 2025 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
VGVasiliki Gkalea
Vasiliki Gkalea
PNPanagiota-Efstathia Nikolaou
Panagiota-Efstathia Nikolaou
TPThomas Pappas
Thomas Pappas
APAlexandra Papadimou
Alexandra Papadimou
JCJulie Courraud
Julie Courraud
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
• Crystalglobulinemia is associated with a procoagulant platelet phenotype and high shear stress-like endothelial alterations. • Markers of platelet and endothelial function reflect monoclonal protein burden.

16 April 2021 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
VGVasiliki Gkalea
Vasiliki Gkalea
XAXavier Amiot
Xavier Amiot
TMThierry Jo Molina
Thierry Jo Molina
LFLaurent Frenzel
Laurent Frenzel
CBClaude Bachmeyer
Claude Bachmeyer
Randall-type monoclonal immunoglobulin deposition disease (MIDD) is an unusual complication of plasma cell disorders with Congo red negative non-organized deposits of monoclonal light chain (LCDD),...